Objective 
Introduction

It is well-known that diabetes changes the thrombohaemorrhagic balance which exists in healthy flowing blood. This change predisposes the diabetic patient to various thromboembolic conditions, leading to increased mortality and mor-bohydrates or increasing intake of rapidly absorbed carbohydrates (ie, high glycemic index) that can create a selfperpetuating insulin resistance state and predicts greater thrombotic risk (5). In the context of insulin resistance, insulin has reduced effects on the phosphatidylinositol 3 kinase (PI3K) pathway, whereas mitogen-activated protein kinase activity is maintained. The result is an exaggeration of the mitogenic actions of insulin leading to vascular smooth muscle proliferation and elevated plasminogen activator inhibitor (PAI)
, the major inhibitor of endogenous thrombolysis, thereby promoting thrombosis (7) . Hyperhomocysteinemia, a consequence of disturbed methionine metabolism, appears also to be an independent risk factor for atherothrombotic events, even in diabetic subjects (8) .
Other factors are involved in the thrombofilic status associated to diabetes, like increased plasma level of XII, XI, and VIII coagulation factors (9) , platelet hypersensitivity to collagen (10) , an increased circulating pool of tissue factor (11) , and sometimes also an increase in Lipoprotein (a) plasma level (12) .
Some antihyperglycemic treatments have demonstrated to reduce blood hypercoagulability in diabetic patients (13) . In particular, metformin, a biguanide, is able to decrease the plasma level of PAI-1 and clotting factor VII (14) , also when associated to sulphanylureas (15) or thiazolidinediones (16) 
Diet and exercise
At baseline, patients began a controlled-energy diet (~600 kcal daily deficit), based on ADA recommendations (21) 
index), and lipid profile [total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg),], lipoprotein(a) Lp(a), fibrinogen (Fg), plasminogen activator inhibitor 1 (PAI-1), tissue-plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), and diastolic blood pressure (DBP
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minute intervals, and the mean of the 3 (25) .
Total cholesterol and Tg levels were determined using fully enzymatic techniques (26, 27) 
Statistical analysis
An intention-to-treat (ITT) analysis was conducted in patients who had received !1 dose of study medication and had a subsequent efficacy observation. Patients were included in the tolerability analysis if they had received !1 dose of trial medication after randomization and had undergone a subsequent tolerability observation. The null hypothesis that the expected mean HbA1c, FPG, PPG, HOMA index change from baseline to 12 months of double-blind treatment did not differ significantly between nateglinide and glibenclamide treatments was tested using analysis of variance and analysis of covariance (ANCOVA) models (38). Similar analyses were applied to Lp(a), Fg, PAI-1, t-PA, and Hcy. The statistical significance of the independent effects of treatments on the other variables was determined using ANCOVA. A 1-sample t test was used to compare values obtained before and after treatment administration; 2-sample t tests were used for between-group comparisons. The Bonferroni correction for multiple comparisons also was carried out. Statistical analysis of data was performed using the Statistical Package for Social Sciences software version 11.0 (SPSS Inc., Chicago, Illinois). Data are presented as mean (SD). For all statistical analyses, p<0.05 was considered statistically significant.
Results
Study sample
Blood pressure
No SBP or DBP change was obtained in the two groups after 3, 6, 9, and 12 months (Tables 1, 2 ). (Fig. 3) . No significant change in Fg and t-PA was seen during the study in each group (Table 1) .
Glycemic control
Lipid profile and lipoprotein variables
No TC, LDL-C, HDL-C, and Tg change was obtained during the study in both groups (Tables 1, 2).
Coagulation and fibrinolysis parameters
Non conventional cardiovascular risk factors
No significant Lp(a), and Hcy change was obtained after 3, 6, and 9 months in both groups. Significant Lp(a), and T a b l e 1 . B a s e l i n e Ch a r a c t e r i s t i c s a n d P a r a me t e r Ch a n g e s a t 3°, 6°, 9°, a n d 1 2° Mo n t h Figs. 4 
o f t h e S t u d y i n Na t e g l i n i d e Gr o u p
and 5).
Discussion
Metformin is a biguanide and its main mechanism of action is to counteract peripheral insulin-resistance (39) . It is the only antihyperglycemic drug that has shown relevant positive effects on hard clinical outcomes: it prevented approximately the 40% of vascular events in a large retrospective study carried out on more than 12,000 patients (40) and it significantly reduced any diabetes-related endpoint in the United Kingdom Prospective Diabetes Study (41) . However, type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia (42) . For patients not taking insulin, accumulating evidence suggests that combination therapy using oral antidiabetic agents with different mechanisms of action may be effective in achieving and maintaining target blood glucose levels (43) .
Glibenclamide is a well-known first generation sulphanylurea (SU). As all SUs, it binds a specific site on the adenosine triphosphate (ATP)-sensitive potassium channels of the SU receptor, subsequently opening calcium channels and thus triggering insulin exocytosis from the pancreatic beta cell (44) .
Nateglinide, a D-phenylalanine derivative lacking either a SU or benzamido moiety, stimulates insulin release via closure of (ATP)-sensitive potassium channels in pancreatic beta-cell, a primary mechanism of action it shares with glibenclamide and other SUs (45) . Nateglinide binds rapidly to the SU SUR1 receptor with a relatively low affinity, and it dissociates from it extremely rapidly in a manner of seconds (46 T a b l e 2 . B a s e l i n e Ch a r a c t e r i s t i c s a n d P a r a me t e r Ch a n g e s a t 3°, 6°, 9°, a n d 1 2° Mo n t h 
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physiological first and early phase of insulin secretion (47) . The association of nateglinide and metformin has already been proven to be an efficacious and safe antidiabetic strategy in type 2 diabetic patients (48) . Its What is more specific in our study is the observation that the nateglinide-treated patients showed a significant reduc-F i g u r e 3 . Ch a n g e i n P AI -1 f r o m b a s e l i n e t o t h a t a t 3 , 6 , 9 , a n d 1 2 mo n t h s i n p a t i e n t s r e c e i v i n g Gl i b e n c l a mi d e o r Na t e g l i n i d e .
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